LF3 is an inhibitor of canonical wnt signaling pathway with IC50 of less than 2 μM. It can disrupt the interaction between β-catenin and TCF4.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | LF3 inhibits Wnt/β-catenin signaling in cells with exogenous reporter genes and in colorectal cancer cells with high intrinsic Wnt activity, with IC50 values of 1.65 μM (β-Catenin/TCF4, AlphaScreen) and 1.82 μM (β-Catenin/TCF4, ELISA). LF3 also suppresses cancer cell traits associated with Wnt signaling, including high cell motility, cell cycle progression, and overexpression of Wnt target genes. However, LF3 does not induce cell death or interfere with cadherin-mediated cell adhesion. Notably, the self-renewal capacity of cancer stem cells is blocked by LF3 in a concentration-dependent manner[1]. |
Dose | NOD/SCID Mice: 50 mg/kg[1] (i.v.) |
Administration | i.v. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02683616 | Obstructive Sleep Apnea ... 展开 >> Fatty Acid Metabolism Continuous Positive Airway Pressure 收起 << | Not Applicable | Recruiting | December 2019 | Czechia ... 展开 >> FN Kralovske Vinohrady Recruiting Prague, Czechia, 10034 Contact: Jan Polak, MD, PhD +420267162710 jan.polak@lf3.cuni.cz Contact: Jan Gojda, MD, PhD +420267168144 jan.gojda@lf3.cuni.cz 收起 << |
NCT03710850 | Insulin Resistance ... 展开 >> Microbiome 收起 << | Not Applicable | Recruiting | December 31, 2021 | Czechia ... 展开 >> University Hospital Kralovske Vinohrady Recruiting Prague, Czechia, 10084 Contact: Jana Potočková +420267163031 klinicka.fyziologie@lf3.cuni.cz 收起 << |
NCT03386461 | Metabolism Disorder ... 展开 >> Adiposity Inflammatory Response 收起 << | Not Applicable | Recruiting | December 2019 | Czechia ... 展开 >> Third Faculty of Medicine, Charles University Recruiting Prague, Czechia, 100 00 Contact: Michaela Siklova, PhD +420 267 102 211 michaela.siklova@lf3.cuni.cz Contact: Lenka Rossmeislova, PhD +420 267 102 211 lenka.rossmeislova@lf3.cuni.cz Principal Investigator: Michaela Siklova, PhD Sub-Investigator: Martin Rossmeisl, PhD Sub-Investigator: Vladimir Stich, prof. MUDr. 收起 << |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.40mL 0.48mL 0.24mL |
12.00mL 2.40mL 1.20mL |
24.01mL 4.80mL 2.40mL |
CAS号 | 664969-54-4 |
分子式 | C20H24N4O2S2 |
分子量 | 416.56 |
SMILES Code | S=C(N1CCN(C/C=C/C2=CC=CC=C2)CC1)NC3=CC=C(S(=O)(N)=O)C=C3 |
MDL No. | MFCD03352482 |
别名 | |
运输 | 蓝冰 |
InChI Key | ZUQIFHLBPBLRRM-QPJJXVBHSA-N |
Pubchem ID | 1213452 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Inert atmosphere, room temperature |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|